Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-133076b034a4711dfc1fe81f7acd828f",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-133076b034a4711dfc1fe81f7acd828f",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-133076b034a4711dfc1fe81f7acd828f",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-133076b034a4711dfc1fe81f7acd828f\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-133076b034a4711dfc1fe81f7acd828f</b></p><a name=\"composition-en-133076b034a4711dfc1fe81f7acd828f\"> </a><a name=\"hccomposition-en-133076b034a4711dfc1fe81f7acd828f\"> </a><a name=\"composition-en-133076b034a4711dfc1fe81f7acd828f-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1351/001 (1 g, 1 vial)</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - trecondi</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/18/1351/001 (1 g, 1 vial)"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp133076b034a4711dfc1fe81f7acd828f"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - trecondi",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Trecondi is and what it is used for</li><li>What you need to know before you are given Trecondi</li><li>How to use Trecondi</li><li>Possible side effects</li><li>How to store Trecondi</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What trecondi is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What trecondi is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Trecondi contains the active substance treosulfan, which belongs to a group of medicines called alkylating agents. Treosulfan is used to prepare patients for bone marrow transplant (haematopoietic stem cell transplantation). Treosulfan destroys the bone marrow cells and enables the transplant of new bone marrow cells which leads to the production of healthy blood cells.</p><p>Trecondi is used as a treatment before blood stem cell transplantation in adults and in adolescents and children older than one month with cancer and non-cancerous disorders.</p></div>"
}
},
{
"title" : "2. What you need to know before you take trecondi",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take trecondi"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Trecondi must not be given to you</p><p>if you are allergic to treosulfan,</p><p>if you suffer from an active uncontrolled infection,</p><p>if you suffer from severe heart, lung, liver or kidney diseases,</p><p>if you suffer from hereditary DNA repair disorder, a condition that reduces the ability to repair DNA (which carries your genetic information),</p><p>if you are pregnant, or think you may be pregnant.</p><p>Warnings and precautions<br/>Trecondi is a cell-killing (cytotoxic) medicine that is used to decrease the number of blood cells. At the recommended dose, this is the desired effect. You will have regular blood tests during treatment to check your blood cell counts do not fall too low.</p><p>In order to prevent and treat infections, you will be given medicines, such as antibiotics, antifungals or antivirals.</p><p>Trecondi may increase the risk of having another cancer in the future.</p><p>Since inflammation of the oral mucosa is a common side effect of this medicine, you should pay attention to adequate oral hygiene. Preventive measures such as the use of mouthwashes (e.g. with barrier protectants, antimicrobials) or application of ice within the oral cavity (lessens blood flow to the oral mucosa and reduces the amount of treosulfan reaching the cell) is recommended.</p><p>You must not receive live vaccines during treatment with treosulfan.</p><p>Trecondi may cause symptoms of the menopause (absence of menstrual periods).</p><p>Children and adolescents Fits (seizures) may occur very rarely in infants of less than 4 months of age. Children younger than 1 year may have more severe side effects that affect breathing than older ones. Your child will be monitored for signs of side effects affecting nerves and breathing problems.</p><p>Nappy rash with sores of the area around the anus (perianal) may occur in infants, toddlers and children wearing nappies because treosulfan passed out in the urine can damage the skin. Therefore, nappies should be changed frequently during 6 8 hours after each dose of this medicine.</p><p>There is not sufficient information on the use of treosulfan in children aged less than 1 month.</p><p>Other medicines and Trecondi Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>Pregnancy, breast-feeding and fertility You must not get pregnant during treatment with this medicine and up to 6 months after treatment. Use an effective method of contraception when either you or your partner is receiving this medicine.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you receive this medicine.</p><p>You should stop breast-feeding before starting treatment with this medicine.</p><p>If you are a man treated with this medicine, you should not father a child during and up to 6 months after treatment.</p><p>This medicine may make you infertile and it may not be possible for you to get pregnant after treatment with it. If you are concerned about having children, you should discuss this with your doctor before treatment. Men should seek advice about the possibility of sperm preservation before starting therapy.</p><p>Driving and using machines This medicine can cause nausea, vomiting and dizziness which may reduce your ability to drive or use machines. If you are affected, do not drive or use machines.</p></div>"
}
},
{
"title" : "3. How to take trecondi",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take trecondi"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Use in adults This medicine is used in combination with fludarabine. The recommended dose is 10 14 g/m body surface area (calculated using your height and weight).</p><p>Use in children and adolescents This medicine is used in combination with fludarabine and in most cases also with thiotepa. The recommended dose is 10 14 g/m body surface area.</p><p>How Trecondi is given This medicine will be given to you by your doctor. It is given by drip (infusion) into a vein over 2 hours for 3 days before blood stem cell infusion.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects The most serious side effects of treosulfan therapy or the transplant procedure include:</p><ul><li>decrease in blood cell counts which is the intended effect of the medicine to prepare you for your transplant infusion (all patients: very common)</li><li>infections caused by bacteria, viruses and fungi (adults: common; children and adolescents: very common)</li><li>blocking of a vein into the liver (adults: uncommon; children and adolescents: not known)</li><li>inflammation of the lung (pneumonitis) (adults: uncommon)</li></ul><p>Your doctor will monitor your blood counts and liver enzymes regularly to detect and manage these events.</p><p>Adults</p><p>A list of all other side effects is set out below according to how common they are.</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>decreased counts of white blood cells with fever (febrile neutropenia)</li><li>inflammation of the lining of various parts of the body, especially in the mouth (which can cause ulcers), diarrhoea, nausea, vomiting</li><li>tiredness</li><li>increased blood level of bilirubin (a liver pigment, often a sign of liver problems)</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>bloodstream infection (sepsis)</li><li>allergic reactions</li><li>decreased appetite</li><li>problems sleeping (insomnia)</li><li>headache, dizziness</li><li>changes and abnormalities in heart rhythm (heartbeat is irregular, too fast or too slow)</li><li>high or low blood pressure, flushing</li><li>difficulty breathing, nosebleeds</li><li>mouth pain, inflammation of the stomach, upset stomach, belly (abdominal) pain, constipation, difficulty in swallowing, gullet or stomach pain</li><li>a type of rash with flat or raised red bumps on the skin (maculopapular rash), red spots on the skin (purpura), redness of skin (erythema), hand and foot syndrome (palms of the hands or soles of the feet tingle, become numb, painfully swollen, or red), itching, hair loss</li><li>pain in arms or legs, back pain, bone pain, joint pain</li><li>sudden decrease of kidney function, blood in the urine</li><li>retention of fluid in the body causing swelling (oedema), fever, chills</li><li>increased liver enzymes, increased C-reactive protein (a marker of inflammation in the body), weight gain, weight loss</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>abnormal control of blood sugar level including high or low blood sugar level</li><li>confusion</li><li>bleeding in the brain, problems in the nerves of the arms or legs with symptoms such as numbness, reduced or increased sensitivity, tingling, burning pain (peripheral sensory neuropathy)</li><li>a spinning sensation (vertigo)</li><li>bruising</li><li>fluid around the lung (pleural effusion), inflammation of throat, inflammation of or pain in voice box, hiccups</li><li>bleeding in the mouth, feeling bloated, dry mouth</li><li>a type of rash with red spots and sometimes with purple or blistered areas in the centre (erythema multiforme), acne, rash, dry skin</li><li>muscle pain</li><li>pain of the urinary tract</li><li>chest pain not related to heart problems, pain</li><li>increased blood level of alkaline phosphatase (your doctor will check for this)</li></ul><p>Not known (frequency cannot be estimated from the available data)</p><ul><li>life-threatening condition after bloodstream infection (septic shock)</li><li>different cancer caused by chemotherapeutic treatment (second malignancy)</li><li>increased acidity in the blood</li><li>abnormal brain function (encephalopathy), restless, repetitive, or involuntary movements and rapid speech (extrapyramidal disorder), fainting, sensation of tingling, pricking or numbness (paraesthesia)</li><li>dry eye</li><li>heart not pumping enough blood for the body s needs (heart failure), heart attack, fluid in the sac around the heart (pericardial effusion)</li><li>blockage of a blood vessel (embolism)</li><li>throat pain, hoarseness, cough</li><li>gastrointestinal bleeding, inflammation of the colon, inflammation of the gullet, inflammation of the anus</li><li>liver injury caused by medicines, enlarged liver</li><li>inflammation of skin (dermatitis), death of skin tissue, skin ulcer, bronze pigmentation of skin</li><li>kidney failure, inflammation of the urinary bladder with bleeding (haemorrhagic cystitis), pain on passing urine (dysuria)</li><li>increased blood level of lactate dehydrogenase (a substance that indicates tissue or cellular damage)</li></ul><p>Children and adolescents</p><p>A list of all other side effects is set out below according to how common they are.</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>inflammation of the mucosa especially in the mouth (with ulcers), diarrhoea, nausea, vomiting, abdominal pain</li><li>liver damage</li><li>itching, hair loss</li><li>fever</li><li>increased blood level of a liver enzyme (ALT)</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>headache</li><li>throat pain, nosebleeds</li><li>difficulty in swallowing, inflammation of anus, mouth pain</li><li>reddening and flaking of most of the skin of the body (dermatitis exfoliative), a type of rash with flat or raised red bumps on the skin (maculopapular rash), rash, redness of skin (erythema), hives, skin pain, bronze pigmentation of skin</li><li>chills</li><li>increased blood level of a liver enzyme (AST) and of bilirubin (a liver pigment, often a sign of liver problems), increased C-reactive protein (a marker of inflammation in the body)</li></ul><p>Not known (frequency cannot be estimated from the available data)</p><ul><li>different cancer caused by chemotherapeutic treatment (second malignancy)</li><li>decreased counts of white blood cells with fever (febrile neutropenia)</li><li>less acid than normal in the blood (alkalosis), abnormal blood level of electrolytes, decreased blood level of magnesium, decreased appetite</li><li>seizure, sensation of tingling, pricking or numbness (paraesthesia)</li><li>bleeding in the eye, dry eye</li><li>leakage of fluid from the capillaries (small blood vessels), high blood pressure, low blood pressure</li><li>decrease in the oxygen supply to parts of the body (hypoxia), cough</li><li>inflammation of the colon, upset stomach, inflammation of the lining of the rectum, pain in the gums, pain in the gullet, constipation</li><li>enlarged liver</li><li>skin ulcer, a type of rash with red spots and sometimes with purple or blistered areas in the centre (erythema multiforme), skin condition with fluid-filled blisters (dermatitis bullous), acne, hand and foot syndrome (palms of the hands or soles of the feet tingle, become numb, painfully swollen, or red), nappy rash with ulceration in the area surrounding the anus</li><li>pain in arms or legs</li><li>decrease of kidney function, kidney failure, inflammation of the urinary bladder (cystitis), blood in the urine</li><li>redness of scrotal skin, pain in the penis</li><li>accumulation of fluid in the tissue that causes swelling in the face, tiredness, pain</li><li>increased blood level of a liver enzyme (gamma-glutamyl transferase)</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store trecondi",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store trecondi"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP . The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>For storage conditions after reconstitution of the medicine, see the information below for healthcare professionals.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Trecondi contains<br/>The active substance is treosulfan. This medicine contains no other ingredients.</p><p>Trecondi 1 g powder for solution for infusion 1 vial of powder contains 1 g of treosulfan.</p><p>Trecondi 5 g powder for solution for infusion 1 vial of powder contains 5 g of treosulfan.</p><p>After reconstitution, 1 mL of the solution contains 50 mg treosulfan.</p><p>What Trecondi looks like and contents of the pack White crystalline powder in a glass vial with a rubber stopper and aluminium cap. Trecondi is available in packs containing 1 or 5 vials (type I glass).</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer medac Gesellschaft f r klinische Spezialpr parate mbH Theaterstr. 6 22880 Wedel Germany Tel.:<br/>+49 4103 8006-0 Fax:<br/>+49 4103 8006-Email: <a href=\"mailto:contact@medac.de\">contact@medac.de</a></p><p>This leaflet was last revised in <{MM/YYYY}><{month YYYY}>.</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp133076b034a4711dfc1fe81f7acd828f",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp133076b034a4711dfc1fe81f7acd828f",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp133076b034a4711dfc1fe81f7acd828f\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp133076b034a4711dfc1fe81f7acd828f</b></p><a name=\"mp133076b034a4711dfc1fe81f7acd828f\"> </a><a name=\"hcmp133076b034a4711dfc1fe81f7acd828f\"> </a><a name=\"mp133076b034a4711dfc1fe81f7acd828f-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1351/001 (1 g, 1 vial)</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Trecondi 1 g powder for solution for infusion</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/18/1351/001 (1 g, 1 vial)"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Trecondi 1 g powder for solution for infusion",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
